Boehringer Ingelheim USFDA Approval Boehringer Ingelheim JASCAYD® (nerandomilast) tablets are  approved by the U.S. FDA as an oral treatment for idiopathic pulmonary fibrosis (IPF) in adult patients. JASCAYD is the first and only preferential inhibitor of phosphodiesterase 4B (PDE4B) to be approved in this indication. This represents a novel mechanism of action that exerts both antifibrotic and immunomodulatory effects, thereby slowing the decline in lung …

Samsung and GRAIL Announce Strategic Collaboration  to Bring GRAIL’s Galleri® Multi-Cancer Early Detection Test to Asia Today, October 16, 2025, Samsung C&T (SCT), Samsung Electronics (SEC), and GRAIL, Inc. (GRAL) announced signing a binding Letter of Intent for a strategic collaboration to bring GRAIL’s GalleriⓇ multi-cancer early detection (MCED) test to . . . This content is for paid subscribers. Please click here to subscribe or …

The Great Story from Regerneron Pharmaceuticals Regeneron Pharmaceuticals (REGN) announced updated data for the Company’s  investigational gene therapy DB-OTO for profound genetic hearing loss due to variants of the otoferlin (OTOF) gene were. The investigation has been published in The New England Journal of Medicine and presented during oral presentation at the annual American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNSF) meeting. The latest results from the pivotal CHORD trial …

Akero Therapeutics Acquisition Agreement Today, October 9, 2025, Akero Therapeutics (AKRO) announced that it entered into a definitive agreement to be acquired by Novo Nordisk (

Neurizon Therapeutics in the NEWS Today October 6, 2025, from Melbourne, Australia: Neurizon Therapeutics Limited (ASX: NUZ & NUZOA), and U.S (ECQO.F), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce that the U.S. FDA has lifted the clinical hold on its lead investigational drug, NUZ-001. This decision marks a pivotal regulatory milestone for Neurizon and the ALS …